Talk:Phosphoinositide 3-kinase inhibitor

Initial focus
Inhibitors of gamma and delta isoforms of PI3K in particular. Rod57 (talk) 19:22, 9 July 2010 (UTC)

Need results of clinical trials
Especially any phase III or even II. Rod57 (talk) 12:32, 25 August 2010 (UTC)

Could describe effects of inhibiting different isoforms
Rod57 (talk) 10:58, 20 October 2010 (UTC)
 * Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors

PI-103
 says "PI-103 is a potent, ATP-competitive PI3K inhibitor of DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ with IC50 of 2 nM, 8 nM, 20 nM, 26 nM, 48 nM, 83 nM, 88 nM and 150 nM, respectively." and implies there have been some clinical trials. says some derivatives of PI-103 such as GDC-0941 have been in clinical trials. Also "GDC-0941 is a potent inhibitor of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ with IC50 of 3 nM, 33 nM, 3 nM and 75 nM, respectively". - Rod57 (talk) 00:10, 24 October 2012 (UTC)

External links modified
Hello fellow Wikipedians,

I have just added archive links to 1 one external link on Phosphoinositide 3-kinase inhibitor. ... I made the following changes:
 * Added archive https://web.archive.org/20090228134004/http://www.bioportfolio.com:80/LeadDiscovery/PubMed-030301.html to http://www.bioportfolio.com/LeadDiscovery/PubMed-030301.html

Cheers.—cyberbot II  Talk to my owner :Online 21:23, 29 January 2016 (UTC)
 * Is it ok to delete this above comment now ? Will do so if no objections - Rod57 (talk) 13:44, 30 January 2017 (UTC)

Should clarify if all are inhibitors of only class I PI3K
Should clarify if all are inhibitors of only class I PI3K - perhaps a section saying what is known about class II, III or IV PI3K inhibitors ? - Rod57 (talk) 13:20, 30 January 2017 (UTC)

External links modified
Hello fellow Wikipedians,

I have just modified 2 external links on Phosphoinositide 3-kinase inhibitor. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added tag to http://www.tradingmarkets.com/news/stock-alert/onty_oncothyreon-presents-phase-1-data-for-px-866-and-px-478-at-asco-annual-meeting-973189.html
 * Added archive https://web.archive.org/web/20160506094809/http://lymphomanewstoday.com/2016/05/02/mei-pharma-announces-new-clinical-data-from-first-in-human-study-of-me-401-a-next-generation-oral-pi3k-delta-inhibitor/ to http://lymphomanewstoday.com/2016/05/02/mei-pharma-announces-new-clinical-data-from-first-in-human-study-of-me-401-a-next-generation-oral-pi3k-delta-inhibitor/
 * Added archive https://web.archive.org/web/20110716035310/http://www.semaforepharma.com/semaforeposterkinase.pdf to http://www.semaforepharma.com/semaforeposterkinase.pdf
 * Added tag to http://rhizen.com/News%20%26%20PR/Rhizen_Press%20Release_ATS_May%2713.pdf

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

Cheers.— InternetArchiveBot  (Report bug) 01:12, 31 March 2017 (UTC)

External links modified
Hello fellow Wikipedians,

I have just modified one external link on Phosphoinositide 3-kinase inhibitor. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added archive https://web.archive.org/web/20130414200852/http://finchannel.com/news_flash/Health%26Beauty/125880_Bayer_to_Present_New_Data_on_Growing_Oncology_Pipeline/ to http://finchannel.com/news_flash/Health%26Beauty/125880_Bayer_to_Present_New_Data_on_Growing_Oncology_Pipeline/

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

Cheers.— InternetArchiveBot  (Report bug) 07:01, 1 April 2017 (UTC)

Duvelisib mentioned in commercial wording
The only drug mentioned as both 'notable example' as well as in "approvals" is Duvelisib. The other approved drugs are not referred to as noteworthy examples. It is also noteworthy that only for duvelisib the tradename is mentioned in the paragraph.

I don't find duvelisib to be an especially noteworthy drug, compared to the other two approved drugs. I also do think stuff like tradename should be part of the respective article for the substance (like it is fine for the other two approved drugs).

Please be aware I do have a COI and thus will not edit the article myself. Wowbagger2 (talk) 10:09, 7 January 2019 (UTC)